Corcept Therapeutics Incorporated (NASDAQ:CORT) Accelerates Into Oncology After FDA Approval
![]() |
March regulatory momentum pushes the company into a commercialization phase while robust liquidity supports near-term execution. Technical momentum coexists with valuation risk, suggesting volatile trading as oncology sales ramp. |








